Successful treatment of primary bone marrow Hodgkin lymphoma with brentuximab vedotin: a case report and review of the literature.
Keiki NagaharuMasahiro MasuyaYuki KageyamaTakanori YamaguchiRyugo ItoKeiki KawakamiMasafumi ItoNaoyuki KatayamaPublished in: Journal of medical case reports (2018)
There is no established treatment strategy for Hodgkin lymphoma, and therapeutic outcomes using ABVD (Adriamycin, bleomycin, vinblastine and dacarbazine)-like or CHOP (cyclophosphamide, Adriamycin, vincristine, and prednisone)-like regimens are reportedly poor. Only a few patients have been reported to achieve long-term remission. Through this case report, we suggest an alternative therapeutic option for primary bone marrow Hodgkin lymphoma.
Keyphrases
- hodgkin lymphoma
- bone marrow
- case report
- mesenchymal stem cells
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- low dose
- diffuse large b cell lymphoma
- high dose
- type diabetes
- metabolic syndrome
- rheumatoid arthritis
- disease activity
- adipose tissue
- skeletal muscle
- patient reported
- weight loss